Alexander G. Petrenko

Alexander G. Petrenko

Auto-generated profile, based on publicly available information

Alexander G. Petrenko

Russian Academy of Sciences

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 May 1992 in Science
Verified
Journal Article
Closed access
PDF file
NBNils Brose
Nils Brose
APAlexander G. Petrenko
Alexander G. Petrenko
TSThomas C. Südhof
Thomas C. Südhof
RJReinhard Jahn
Reinhard Jahn
Neurons release neurotransmitters by calcium-dependent exocytosis of synaptic vesicles. However, the molecular steps transducing the calcium signal into membrane fusion are still an enigma. It is reported here that synaptotagmin, a highly conserved synaptic vesicle protein, binds calcium at physiological concentrations in a complex with negatively charged phospholipids. This binding is specific for calcium and involves the cytoplasmic domain of synaptotagmin. Calcium binding is dependent on the intact oligomeric structure of synaptotagmin (it is abolished by proteclytic cleavage at a single site). These results suggest that synaptotagmin acts as a cooperative calcium receptor in exocytosis.

3 July 1992 in Science
Verified
Journal Article
Closed access
PDF file
YUYuri A. Ushkaryov
Yuri A. Ushkaryov
APAlexander G. Petrenko
Alexander G. Petrenko
MGMartin Geppert
Martin Geppert
TSThomas C. Südhof
Thomas C. Südhof
A family of highly polymorphic neuronal cell surface proteins, the neurexins, has been identified. At least two genes for neurexins exist. Each gene uses alternative promoters and multiple variably spliced exons to potentially generate more than a 100 different neurexin transcripts. The neurexins were discovered by the identification of one member of the family as the receptor for α-latrotoxin. This toxin is a component of the venom from black widow spiders; it binds to presynaptic nerve terminals and triggers massive neurotransmitter release. Neurexins contain single transmembrane regions and extracellular domains with repeated sequences similar to sequences in laminin A, slit, and agrin, proteins that have been implicated in axon guidance and synaptogenesis. An antibody to neurexin I showed highly concentrated immunoreactivity at the synapse. The polymorphic structure of the neurexins, their neural localization, and their sequence similarity to proteins associated with neurogenesis suggest a function as cell recognition molecules in the nerve terminal.

1 June 1997 in Neuron
Verified
Journal Article
Open access
VKValery G Krasnoperov
Valery G Krasnoperov
MBMary A Bittner
Mary A Bittner
RBRonald Beavis
Ronald Beavis
YKYanan Kuang
Yanan Kuang
KSKonstantin V Salnikow
Konstantin V Salnikow
APAlexander G Petrenko
Alexander G Petrenko
Alpha-Latrotoxin is a potent stimulator of neurosecretion. Its action requires extracellular binding to high affinity presynaptic receptors. Neurexin I alpha was previously described as a high affinity alpha-latrotoxin receptor that binds the toxin only in the presence of calcium ions. Therefore, the interaction of alpha-latrotoxin with neurexin I alpha cannot explain how alpha-latrotoxin stimulates neurotransmitter release in the absence of calcium. We describe molecular cloning and functional expression of the calcium-independent receptor of alpha-latrotoxin (CIRL), which is a second high affinity alpha-latrotoxin receptor that may be the major mediator of alpha-latrotoxin's effects. CIRL appears to be a novel orphan G-protein-coupled receptor, a member of the secretin receptor family. In contrast with other known serpentine receptors, CIRL has two subunits of the 120 and 85 kDa that are the result of endogenous proteolytic cleavage of a precursor polypeptide. CIRL is found in brain where it is enriched in the striatum and cortex. Expression of CIRL in chromaffin cells increases the sensitivity of the cells to the effects of alpha-latrotoxin, demonstrating that this protein is functional in coupling to secretion. Syntaxin, a component of the fusion complex, copurifies with CIRL on an alpha-latrotoxin affinity column and forms stable complexes with this receptor in vitro. Interaction of CIRL with a specific presynaptic neurotoxin and with a component of the docking-fusion machinery suggests its role in regulation of neurosecretion.

1 September 1991 in Nature
Verified
Journal Article
Closed access
APAlexander G. Petrenko
Alexander G. Petrenko
MPMark S. Perin
Mark S. Perin
BDBazbek A. Davletov
Bazbek A. Davletov
YUYuri Ushkaryov
Yuri Ushkaryov
MGMartin Geppert
Martin Geppert
TSThomas C. Südhof
Thomas C. Südhof

30 December 2005 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
NPNatalia A. Ponomarenko
Natalia A. Ponomarenko
ODOxana M. Durova
Oxana M. Durova
IVIvan Ivanovich Vorobiev
Ivan Ivanovich Vorobiev
ABAlexey A. Belogurov
Alexey A. Belogurov
IKInna N. Kurkova
Inna N. Kurkova
AGAlexander Gabibov
Alexander Gabibov
Autoantibody-mediated tissue destruction is among the main features of organ-specific autoimmunity. This report describes “an antibody enzyme” (abzyme) contribution to the site-specific degradation of a neural antigen. We detected proteolytic activity toward myelin basic protein (MBP) in the fraction of antibodies purified from the sera of humans with multiple sclerosis (MS) and mice with induced experimental allergic encephalomyelitis. Chromatography and zymography data demonstrated that the proteolytic activity of this preparation was exclusively associated with the antibodies. No activity was found in the IgG fraction of healthy donors. The human and murine abzymes efficiently cleaved MBP but not other protein substrates tested. The sites of MBP cleavage determined by mass spectrometry were localized within immunodominant regions of MBP. The abzymes could also cleave recombinant substrates containing encephalytogenic MBP85-101peptide. An established MS therapeutic Copaxone appeared to be a specific abzyme inhibitor. Thus, the discovered epitope-specific antibody-mediated degradation of MBP suggests a mechanistic explanation of the slow development of neurodegeneration associated with MS.

1 February 1993 in Neuron
Verified
Journal Article
Closed access
YHYutaka Hata
Yutaka Hata
BDBazbek Davletov
Bazbek Davletov
APAlexander G. Petrenko
Alexander G. Petrenko
RJReinhard Jahn
Reinhard Jahn
TSThomas C. Südhof
Thomas C. Südhof